Announcement

Collapse
No announcement yet.

Neuralstem updates clinical trial progress

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Neuralstem updates clinical trial progress

    Public release date: 14-Jun-2011
    [ Print | E-mail | Share ] [ Close Window ]

    Contact: Deanne Eagle
    deanneeagle@gmail.com
    917-837-5866
    Neuralstem, Inc.

    Neuralstem updates clinical trial progress
    Approved by Safety Monitoring Board to move to cervical transplantations


    Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first twelve patients, all of whom received injections in the lumbar region of the spine only, the trial's Safety Monitoring Board (SMB) has unanimously approved advancing the trial to transplantions in cervical region. The next three patients, all of whom are ambulatory, will each receive five injections, unilaterally, in the cervical spinal cord. In addition to the SMB approval, the FDA must also approve the trial's moving to the next level of transplantations. The company expects to present the data from the first twelve patients to the FDA in the near future.

    "We are delighted to have completed the first part of the safety trial," commented Eva Feldman, MD, PhD, Principal Investigator of the trial and an unpaid consultant to Neuralstem. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. "We have been pleased with the smooth progress of the trial thus far, from non-ambulatory to ambulatory patients, who have an earlier stage of the disease. We are particularly excited to begin the cervical injections, once we've received FDA approval. While this is still primarily a safety trial, it is our hope that cervical injections can help the patient's breathing and swallowing, the areas which most often lead to loss of life in ALS."

    read...

    http://www.eurekalert.org/pub_releas...-nuc061411.php

    #2
    Neuralstem's video is very positive, as if its spinal cord injury stem cell transplant has an absolutely positive effect. Surely we would have all heard something if that were the case?

    Comment


      #3
      Originally posted by Christopher Paddon View Post
      Neuralstem's video is very positive, as if its spinal cord injury stem cell transplant has an absolutely positive effect. Surely we would have all heard something if that were the case?
      Christopher, this is for amyotrophic lateral sclerosis. I don't think that they have reported functional improvement yet.

      Wise.

      Comment

      Working...
      X